Therapy Areas: Autoimmune
Genentech reports positive Phase III MAJESTYdata for Gazyva in primary membranous nephropathy
16 February 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), on Monday reported positive Phase III results from the MAJESTY study evaluating Gazyva (o...
STADA and Bio-Thera Solutions receive European marketing authorisation for Gotenfia (golimumab)
16 February 2026 - Specialty, generic and consumer healthcare medicines company STADA and Bio-Thera Solutions (SH:688177), a commercial-stage biopharmaceutical company, announced on Friday that they h...
Amgen wins European approval for Uplizna in generalised myasthenia gravis
Akeso's AK139 Phase II clinical trials approved in China
12 February 2026 - Hong Kong-based biopharmaceutical company Akeso Inc (HK:9926) announced on Wednesday that it has received approval from China's National Medical Products Administration for the...
Eli Lilly signs definitive agreement to acquire Orna Therapeutics
10 February 2026 - US pharmaceutical company Eli Lilly and Company (NYSE:LLY) announced on Monday that it has signed a definitive agreement to acquire Orna Therapeutics Inc, a biotechnology company fo...
Sanofi's rilzabrutinib receives FDA breakthrough and Japan orphan designations for rare anaemia
9 February 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Monday that the US Food and Drug Administration (FDA) has granted breakthrough therapy designatio...